For the first time, the annual ChinaBio® Partnering Forum, which will be held next week, features a Partnering Bootcamp, a half-day pre-conference program; China National Biotech Group (CNBG), the nation’s biggest biotech company, will stage a $1.6 billion IPO in Hong Kong; Zhejiang Conba Pharma raised $148 million via a private placement; Ningbo David Medical Device completed a $63.5 million IPO on the ChiNext Exchange; Ventac Partners in-licensed potential diabetes 2 treatments from Guangzhou Institute of Biomedicine and Health; Shanxi Zhendong Pharmaceutical Company and the Shanxi College of Traditional Chinese Medicine banded together with the University of Adelaide in Australia to study the molecular basis of TCM; Johnson & Johnson is actively pursuing M&A in China as a way to increase its revenue growth; Bristol-Myers Squibb formed a multi-year strategic partnership with Tsinghua University of Beijing and invested $20 million to expand its China manufacturing capacity; Baxter International received SFDA approval for its recombinant treatment of hemophilia A; Novozymes Biopharma has begun selling hyaluronic acid made at its new Tianjin facility; and Zhejiang Hisun Pharma will manufacture ThermoDox®, a clinical-stage liver cancer drug, for Celsion of the US. More details…. Stock Symbols: (SHA: 600572) (SHE: 300314) (SHE: 300158) (NYSE: JNJ) (NYSE:BMY) (NYSE: BAX) (NSDQ OMX: Copenhagen: NZYM B) (SHA: 600267) (NSDQ: CLSN) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});